Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975

被引:147
作者
Efficace, F.
Bottomley, A.
Smit, E. F.
Lianes, P.
Legrand, C.
Debruyne, C.
Schramel, F.
Smit, H. J.
Gaafar, R.
Biesma, B.
Manegold, C.
Coens, C.
Giaccone, G.
Van Meerbeeck, J.
机构
[1] European Org Res Treatment Canc, Ctr Data, Qual Life Unit, B-1200 Brussels, Belgium
[2] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[3] Hosp Mataro, Mataro, Spain
[4] St Antonius Hosp, Nieuwegein, Netherlands
[5] Rijnstate Hosp Arnhem, Arnhem, Netherlands
[6] Natl Canc Inst, Cairo, Egypt
[7] Jeroen Bosch Ziekenhuis sHertogenbosch, Shertogenbosch, Netherlands
[8] Univ Med Ctr, Mannheim, Germany
[9] Univ Hosp, Ghent, Belgium
关键词
lung cancer; prognostic factor; quality of life; survival;
D O I
10.1093/annonc/mdl183
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The aim of this prognostic factor analysis was to investigate if a patient's self-reported health-related quality of life (HRQOL) provided independent prognostic information for survival in non-small cell lung cancer (NSCLC) patients. Patients and methods: Pretreatment HRQOL was measured in 391 advanced NSCLC patients using the EORTC QLQ-C30 and the EORTC Lung Cancer module (QLQ-LC13). The Cox proportional hazards regression model was used for both univariate and multivariate analyses of survival. In addition, a bootstrap validation technique was used to assess the stability of the outcomes. Results: The final multivariate Cox regression model retained four parameters as independent prognostic factors for survival: male gender with a hazard ratio (HR) = 1.32 (95% CI 1.03-1.69; P = 0.03); performance status (0 to 1 versus 2) with HR = 1.63 (95% CI 1.04-2.54; P = 0.032); patient's self-reported score of pain with HR= 1.11 (95% CI 1.07-1.16; P < 0.001) and dysphagia with HR = 1.12 (95% CI 1.04-1.21; P = 0.003). A 10-point shift worse in the scale measuring pain and dysphagia translated into an 11% and 12% increased in the likelihood of death respectively. A risk group categorization was also developed. Conclusion: The results suggest that patients' self-reported HRQOL provide independent prognostic information for survival. This finding supports the collection of such data in routine clinical practice.
引用
收藏
页码:1698 / 1704
页数:7
相关论文
共 29 条
[21]   The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy [J].
Langendijk, H ;
Aaronson, NK ;
de Jong, JMA ;
ten Velde, GPM ;
Muller, MJ ;
Wouters, M .
RADIOTHERAPY AND ONCOLOGY, 2000, 55 (01) :19-25
[22]   Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy:: A prognostic analysis of the Multicenter Italian Lung Cancer in the Elderly Study [J].
Maione, P ;
Perrone, F ;
Gallo, C ;
Manzione, L ;
Piantedosi, FV ;
Barbera, S ;
Cigolari, S ;
Rosetti, F ;
Piazza, E ;
Robbiati, SF ;
Bertetto, O ;
Novello, S ;
Migliorino, MR ;
Favaretto, A ;
Spatafora, M ;
Ferraù, F ;
Frontini, L ;
Bearz, A ;
Repetto, L ;
Gridelli, C .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :6865-6872
[23]   Baseline quality of life predicts survival in patients with advanced colorectal cancer [J].
Maisey, NR ;
Norman, A ;
Watson, M ;
Allen, MJ ;
Hill, ME ;
Cunningham, D .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (10) :1351-1357
[24]   Quality of life in lung cancer patients - As an important prognostic factor [J].
Montazeri, A ;
Milroy, R ;
Hole, D ;
McEwen, J ;
Gillis, CR .
LUNG CANCER, 2001, 31 (2-3) :233-240
[25]   A BOOTSTRAP RESAMPLING PROCEDURE FOR MODEL-BUILDING - APPLICATION TO THE COX REGRESSION-MODEL [J].
SAUERBREI, W ;
SCHUMACHER, M .
STATISTICS IN MEDICINE, 1992, 11 (16) :2093-2109
[26]   QUALITY-OF-LIFE IN PHASE-II TRIALS - A STUDY OF METHODOLOGY AND PREDICTIVE VALUE IN PATIENTS WITH ADVANCED BREAST-CANCER TREATED WITH PACLITAXEL PLUS GRANULOCYTE-COLONY-STIMULATING FACTOR [J].
SEIDMAN, AD ;
PORTENOY, R ;
YAO, TJ ;
LEPORE, J ;
MONT, EK ;
KORTMANSKY, J ;
ONETTO, N ;
REN, L ;
GRECHKO, J ;
BELTANGADY, M ;
USAKEWICZ, J ;
SOUHRADA, M ;
HOUSTON, C ;
MCCABE, M ;
SALVAGGIO, R ;
THALER, H ;
NORTON, L .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (17) :1316-1322
[27]   Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975 [J].
Smit, EF ;
van Meerbeeck, JPAM ;
Lianes, P ;
Debruyne, C ;
Legrand, C ;
Schramel, F ;
Smit, H ;
Gaafar, R ;
Biesma, B ;
Manegold, C ;
Neymark, N ;
Giaccone, G .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3909-3917
[28]   Health-related quality of life in patients with glioblastoma: a randomised controlled trial [J].
Taphoorn, MJB ;
Stupp, R ;
Coens, C ;
Osoba, D ;
Kortmann, R ;
van den Bent, MJ ;
Mason, W ;
Mirimanoff, RO ;
Baumert, BG ;
Eisenhauer, E ;
Forsyth, P ;
Bottomley, A .
LANCET ONCOLOGY, 2005, 6 (12) :937-944
[29]   Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection [J].
Van Steen, K ;
Curran, D ;
Kramer, J ;
Molenberghs, G ;
Van Vreckem, A ;
Bottomley, A ;
Sylvester, R .
STATISTICS IN MEDICINE, 2002, 21 (24) :3865-3884